PLEASANTON, Calif., May 4 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR - News), a world leader in products to treat cardiovascular disease, today said that the FDA has approved an IDE (Investigational Device Exemption) supplement that allows enrollment of up to an additional 60 patients in the Bridge-to-Transplantation (BTT) arm of the company’s HeartMate II Phase II trial under a Continued Access Protocol (CAP).
